Table 1

Clinical characteristics of the patients in the two groups

Alogliptin treatment groupConventional treatment group
n = 172n = 169P value
Male sex101 (63)98 (61)0.72
Age (years)64.4 ± 9.864.8 ± 9.10.82
Current smoking43 (27)33 (21)0.24
Hypertension90 (56)91 (57)1.00
Dyslipidemia86 (53)94 (58)0.43
Duration of T2DM (years)9 (5.0, 15.0)8.2 (4.0, 15.0)0.94
Use of oral glucose-lowering agents
 Metformin84 (52)75 (47)0.37
 Sulfonylurea80 (50)90 (56)0.32
 Glinides9 (6)16 (10)0.21
 Thiazolidinediones35 (22)38 (24)0.79
 α-Glucosidase inhibitor56 (35)51 (32)0.64
Use of antihypertensive drugs
 ACE inhibitors7 (4)4 (2)0.54
 Angiotensin II receptor blockers72 (45)68 (42)0.74
 Direct renin inhibitor0 (0)1 (1)1.00
 Calcium channel blocker47 (29)58 (36)0.23
 Diuretic drugs7 (4)8 (5)1.00
 α-Adrenergic receptor antagonist3 (2)0 (0)0.25
 β-Adrenergic receptor antagonist3 (2)8 (5)0.22
 Others1 (0)4 (2)0.37
Use of lipid-lowering agents
 Statins61 (38)74 (46)0.18
 Ezetimibe5 (3)2 (1)0.45
 Resins0 (0)1 (1)1.00
 Fibrates6 (4)9 (6)0.60
Use of antithrombotic agents
 Antiplatelet agents19 (12)23 (14)0.62
 Anticoagulants1 (1)3 (2)0.62
 Others0 (0)1 (1)1.00
  • Data are n (%), mean ± SD, or median (interquartile range).